Agency for Science, Technology and Research

Singapore Health Services Pte Ltd

Merck Sharp + Dohme Corp.

Tan Tock Seng Hospital Pte Ltd

Msd International Gmbh (singapore Branch)

Msd International Gmbh

Chandra Shekhar Verma

Jing Ya Li

Roger Wilmer Beuerman

Donald Tan

Shouping Liu

Lei Zhou

Tomi K Sawyer

David Philip Lane

Sookhee Nicole Ha

Nicolas Cedric Boyer

Chunhui Huang

Charles William Johannes

Christopher John Brown

Tiang Hwee Donald Tan

Tsz Ying Yuen

Swaine Chen

Lakshminarayanan Rajamani

Pietro Aronica

Anthony W Partridge

Jianguo Li

Mercy Halleluyah Periayah

Timothy Barkham

Jun Jie Koh

Thet Tun Aung

Srinivasaraghavan Kannan

Michael B Garrigou

Yaw Sing Tan

Anita Suresh

Fernando Jose Ferrer Gago

Thomas Joseph

Fernando J Ferrer

Hanxun Zou

Lakshminiarayan Rajanmani

Saraswathi Padmanabhan

Christoper J Brown

Chang Chui Charles Tang

The present invention relates to a compound comprising a hydrophobic moiety, a linker and N-containing moiety. The present invention also relates to the method of synthesizing the compound and the use of the compound as an antibiotic or an adjuvant for an antibiotic.

Molecular design of new antibiotics and antibiotic adjuvants against MCR strains

The invention provides compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (K-Ras) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant

The present invention relates to non-membrane disruptive and p53 activating stapled peptides, as well as methods of treatment of cancer involving the use of these peptides. In one embodiment, the peptide comprises or consist of the amino acid sequence of TSFXaaEY-WXaaLLXaa, where Xaais (R)-2-(7'-octenyl)alanine or derivative thereof, or is (R)-2-(4&#x2032;-pentenyl)alanine or derivative thereof; and Xaaand Xaaare independently any type of amino acid or modified amino acid. In another embodiment, the peptide comprising or consisting of the amino acid sequence of TSFXaaEYW XaaLLXaaENXaa, wherein Xaaand Xaaare any type of amino acid or modified amino acid; Xaais S, or P, or (S)-2-(4&#x2032;-pentenyl)alanine or a derivative of (S)-2-(4&#x2032;-pentenyl)alanine; and wherein Xaais F or Y.

Non-membrane disruptive P53 activating stapled peptides

The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3. The method includes a composition or combination comprising the multimeric antimicrobial peptides and at least one active pharmaceutical ingredient.

Multimeric forms of antimicrobial peptides

The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.

There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.

Antimicrobial peptides

Growing community of inventors

Singapore, Singapore

Chandra Shekhar Verma